COVID-19 HG INITIATIVE
Allelica has built the platform for the COVID-19 HG Initiative to collect clinical data from hospitalized patients.
Genomic Risk Prediction
of Complex Diseases
Seamlessly in the Cloud
Allelica allows the computation of Polygenic Risk Score based on Thousands or Millions of genetic variants.
Upload genotype data and Allelica performs QC, imputation, risk modelling and results visualisation.
For Clinical Genetics Labs
Offer your customers the latest PRS for clinical grade risk prediction. Upload your SNP array or NGS data and our software performs PRS analysis in a cloud architecture that is fully automated, GDPR-HIPAA compliant and certified as a Medical Device. Differentiate your clinic from the crowd, embrace data-driven healthcare and generate a new source of revenue.
For Researchers
You’re just two clicks away from your next PRS paper. Use our platform to perform the entire PRS pipeline, QC and imputation, without writing a single line of code. Run and compare the performance of the most cited PRS methods, such as LD-Pred and Clumping and Thresholding. Focus only on what really matters for your research project without the hassle of informatics.
For Pharmas
Stratify participants of your clinical trials according to their genomic diversity. Use our software to identify individuals at with different underlying risk so that you can target your trial population saving your company money and time while having a better trial outcome. A simple genotyping array unlocks precious information on your cohort, invaluable to follow up decision-making in the modern area of drug development.
Trusted Translational Genomics
Allelica has built the first cloud platform that allows you to perform Polygenic Risk Score (PRS) analysis without writing a single line of code. The cloud architecture is a secure and trusted environment that has been certified as a Medical Device and is GDPR and HIPAA complaint. We work with leading clinical genetics labs, pharmaceutical companies and research institutes to improve health care prevention for a large number of complex diseases. The cloud platform accepts as input genotyping array and NGS data, performs genomic prediction analysis with published PRS or with your newly developed PRS.
Validation and testing on the UKBiobank is performed with just two clicks.
"With this agreement, Merck confirms its strong commitment in advancing Science and Technology in the therapeutic area of cardiovascular disorders"
Antonio Messina, Merck General Manager
Development of data-driven cardiovascular disease prevention tools
Allelica is partnering with Merck, a leading global hearthcare and life sciences company, to develop a suite of tools designed to help cardiovascular disease patients. Whilst cardiovascular diseases are the leading cause of mortality worldwide, there is a growing number of patients who survive initial cardiovascular events and require secondary prevention measures. Allelica's work with Merck is aimed at improving the patient journey by exploring how technology can be used to identify patients who may have unknowingly suffered heart failure and those at high risk of a secondary cardiovascular event.
The Latest from Allelica
Abstract accepted for presentation! Giordano Bottà CEO & Co-Founder of Allelica will describe how the risk of Coronary Artery Disease conferred by Low-Density Lipoprotein Cholesterol depends on our polygenic background. We're proud to be part of the largest European conference of cardiology. This year ESC will be completely digital. We hope you'll take the opportunity to remotely attend this great event and enjoy our talk.
Abstract accepted for oral presentation! We were excited to share the latest results on how the integration of a cutting edge Polygenic Risk Score in CAD absolute risk models improves their predictive power and reclassifies individuals in the correct risk categories. Due to COVID-19 pandemia the conference was cancelled. The virus did not allow us to meet in person, but it can't stop the sharing of knowledge and high quality science. The presentation will be available online in the next coming days.
Allelica presented at the Personalized and Precision Medicine International Conference – PEMED 2020 in Munchen the research study on the integration of Coronary Artery Disease Polygenic Risk Score in clinical risk models. This annual Personalized and Precision Medicine International Conference gathered the best experts in the field to meet and discuss with the aim of translating precision medicine into direct improvements in health care.
Allelica attended the GenomicsLive Conference in Basel, Switzerland - December 2019. The Europe’s leading conference designed to deliver diagnostics and digital technologies into the clinic. The event covered diagnostics, digital pathology and clinical aspects of precision medicine.
At the “ESC 2019 together with World Congress of Cardiology”, held in Paris in the first week of September 2019, Allelica presented the newly developed software to compute Polygenic Risk Score (PRS) for Coronary Artery Disease. The clinical value of integrating PRS in traditional risk models was also discussed.
Are you a new grad or someone interested in polygenic [risk] scores, genetics, open data resources, and learning about scientific #curation? We’re looking for a #trainee/#intern to join our team @PGSCatalog @emblebi!
Application + info: https://www.embl.de/jobs/searchjobs/index.php?ref=EBI01654
#sciencejobs
The DISCOVER module enables users to build & validate new polygenic risk scores using large genetic datasets & state-of-the-art algorithms. Learn more: https://bit.ly/2VOZysk #genomics #genetics #PrecisionMedicine #digitalhealth
“We show that PRS have potential for risk stratification for cancers of breast, colon and prostate, but less so for others because of modest heritability and lower incidence.”
Great to see further evidences of clinical utility for breast and prostate cancer PRS.
Great to see our paper on evaluating polygenic architecture and utility of PRS across 14 cancers appear online @NatureComms, providing a roadmap for future of GWAS and PRS. Fantastic collaboration @mgarciaclosas @happy_dora1 and #CancerGWASConsortia. https://www.nature.com/articles/s41467-020-16483-3 https://twitter.com/nilanjan10c/status/1159990770394435584
Why you should choose Allelica
Made by scientists
Allelica software and algorithms have been developed thanks to a collaboration between scientists who carried out resarches at Oxford University and the University of Rome “La Sapienza”.
Software as a Service
Use our SaaS for easy and fast data analysis and report. Use our pipelines to safely scale your genomic anaysis.
Privacy and Security
We give absolute priority to the privacy of your data. The genetic data are encoded through a secure protocol and encrypted in a single tenant node.
What we do
Perform Risk Prediction Analysis
Use the Allelica in Cloud software to perform Polygenic Risk Score Analysis in a fast and safe way.
Preventive Healthcare
Provide the latest clinical grade Polygenic Risk Score for complex diseases published on high impact factor journals.
Appeared on
Allelica founders carried out research at the University of
Funded by
The European project for innovation in Health
The Seed Fund
The Italian Pree-Seed grant to support Research Spin-Off
